Sulfadiazine Silver

磺胺嘧啶银

Report date: 2022/01/14 13:23:58
NME

Base Information

Drug NameSulfadiazine Silver
Drug Alias NameSulfadiazinum ArgenticumSulfadiazinum ArgentumSulfadiazine ArgentiqueHopeasulfadiatsiiniSilver sulfadiazine +[12] 
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionDNA binders
TargetsDNA
Therapy Area/IndicationsTibial FracturesBurnsWounds and Injuries +[4] 
Global Approved IndicationsWounds and InjuriesSepsis
Approved Indications in ChinaWounds and Injuries
Original Approved Country/TerritoryUnited States
Original Approved Date1973/11/26
Country/TerritoryUnited StatesThailandIran +[5] 
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaApproved
Originator CompaniesPfizer Inc
China Registration ClassN/A

Develop Information

Active CompaniesPfizer IncKing Pharmaceuticals IncTianjin Pharmaceutical Peace (Tianjin) Pharmaceutical Co Ltd
Inactive CompaniesScarm Institute, Tabriz, IranNucleo De Pesquisa E Desenvolvimento De Medicamentos Da Universidade Federal Do CearaPrince Of Songkla University +[4] 
Active IndicationsWounds and InjuriesSepsis
Inactive IndicationsTibial FracturesBurns

Other Information

ATC CodeJ01EC02
Related LinksWikipediaDrugBankKEGG